Major Adverse Cardiovascular Events of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors Among Patients With Different Malignancy: a Systemic Review and Network Meta-Analysis
Source : https://journals.lww.com/jcma/abstract/9900/major_adverse_cardiovascular_events_of_vascular.304.aspx
We searched PubMed, Embase, and ClinicalTrials.gov from inception until August 31, 2021, for phase II/III randomized controlled trials of 11 VEGF-TKIs (axitinib, cabozantinib, lenvatinib, pazopanib, ponatinib, ripretinib, regorafenib, sorafenib, sunitinib,...
The risk of heart failure significantly increased in association with less selective sorafenib (OR: 3.53), pazopanib (OR: 3.10), and sunitinib (OR: 2.65).
Cardiovascular and Renal Benefit of Novel Non-Steroidal Mineralocorticoid Antagonists in Patients with Diabetes
Source : https://link.springer.com/article/10.1007/s11886-023-01998-0
Novel non-steroidal mineralocorticoid receptor (MR) antagonists (MRAs) are a new class of drugs blocking adverse MR-mediated effects with an improved benefit-risk profile compared to steroidal MRAs. This review will provide...
This review provide information’s on the preclinical and clinical pharmacology of this new drug class and will discuss its future clinical applications in patients with cardiorenal disease.
Cumulative HbA1c Exposure as a CVD Risk in Patients With Type 2 Diabetes: a Post Hoc Analysis of ACCORD Trial
Source : https://pubmed.ncbi.nlm.nih.gov/37952600/
Higher cumulative HbA1c exposure was significantly associated with an increased risk of the primary outcome, all-cause mortality and cardiovascular death among T2D patients.
Participants in the intensive-therapy group with high baseline HbA1c and cumulative HbA1c exposure had a significantly higher risk of primary outcome, all-cause mortality, and CV-related death.
Neuropeptide Y Is Elevated in Heart Failure and Is an Independent Predictor of Outcomes
Source : https://pubmed.ncbi.nlm.nih.gov/37937329/
Peripherally measured NPY is an independent predictor of all-cause and cardiovascular death even after adjustment for other prognostic variables, including BNP.
Peripherally measured NPY is an independent predictor of all cause and CV death even after adjustment for other prognostic variables, including BNP.
Use of MHT in Women With Cardiovascular Disease: a Systematic Review and Meta-Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/37933495/
This systematic review assesses the effect of menopausal hormone therapy (MHT) on cardiovascular outcomes and risk factors in postmenopausal women with cardiovascular disease (CVD).
No significant differences were observed between MHT users and controls regarding primary outcomes of nonfatal MI, CV-related death, or stroke. No differences in frequency of angina, HF, and TIAs were observed.